Semaglutide Carries Potential Risk of Worsening Diabetic Retinopathy
Despite demonstrating numerous benefits, semaglutide has also been linked to an increased incidence of diabetic retinopathy, which was initially reported in the SUSTAIN-6 trial.
Read More
TXNIP inhibitors: A New Class of Agents for Diabetes Treatment
TXNIP inhibition could prevent beta cell loss and protect beta cell function to potentially contribute to diabetes management and its complications.
Read More